Skip to content
Future from a16z

A new site for understanding the future, how tech shapes it, and how we build it.

Go to Future
It's time to build
Nav Opener
  • Portfolio
  • Team
  • Focus Areas
    • American Dynamism
    • Bio + Health
    • Cultural Leadership Fund
    • Consumer
    • Crypto
    • Enterprise
    • Fintech
    • Games
    • Growth
    • Talent x Opportunity
  • Content
    Topics
    • Fintech
    • Gaming & Social
    • Security & Privacy
    • Marketplaces
    • Enterprise & SaaS
    • Bio + Health
    • Creator Economy
    • Cryptocurrencies & Blockchains
    Type
    • Articles
    • Video
    • Podcasts
    • Newsletters
  • About
  • Jobs
Close

Jorge Conde

Jorge Conde Download Photo Twitter

Jorge Conde is a General Partner at Andreessen Horowitz, where he leads investments at the cross section of biology, computer science, and engineering. Jorge has more than 20 years of experience in leading, building, operating, and investing in life sciences and healthcare, with a broad range of operational roles in early-stage and commercial companies.

Prior to joining a16z, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros (NASDAQ: SYRS), which is advancing small molecules to control the expression of genes. Jorge was also co-founder and CEO of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

Jorge holds an MBA from Harvard Business School, an M.S. from the Harvard-MIT Division of Health Sciences and Technology, and a B.A. in Biology from Johns Hopkins University.

Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.

Jorge currently serves on the boards of the following Andreessen Horowitz portfolio companies: Aria, Asimov, Camp4, Dyno, Earli, EQRx, Komodo Health, Octant Bio, and Tmunity.

Latest Posts

Anatomy of a Biotech Business Development Deal

by Jorge Conde and Becky Pferdehirt
  • bio + health

New Year, New Fund, New Opportunities in Bio + Health

by Vineeta Agarwala, Jorge Conde, Justin Larkin, Vijay Pande, Becky Pferdehirt, Jay Rughani, Judy Savitskaya, Daisy Wolf, and Julie Yoo
  • bio + health
  • announcements
  • gene editing including CRISPR
  • healthcare
  • therapeutics
  • when science becomes engineering

Platform-Partnership Fit: A Guide to Business Development for Bio Startups

by Jorge Conde and Jay Rughani
  • bio + health
  • go to market
  • the bio platforms playbook

Bio Eats World: Discovery, Translation, and the State of Bio Today

by Jorge Conde
  • bio + health
  • Digital Health Builders

From @jorgecondebio

Jorge Conde@JorgeCondeBio

Rule #1 of Hollywood moviemaking: for any given franchise, the main villain of one of the movies must be an evil biotechnology company. 🧬 😈

Jorge Conde@JorgeCondeBio

πŸš€ πŸ‡ΊπŸ‡Έ πŸš€ https://t.co/USLH7epbsJ

Vineeta Agarwala@vintweeta

Excited to be in Chicago for #ASCO22! A few @a16z bio + health folks are here β€” please stop by to say hello tonight (Saturday eve). DM us for details, we would love to see you! πŸ‘‹πŸΌ a16z Bio+Health ASCO Reception Sat June 4th | 5:30-7:30pm CT cc @JayRughani @GingerLiau @kkerames https://t.co/xdVVmXMRVF

Software is eating the world
© 2022 Andreessen Horowitz
Software is eating the world
    • Twitter
    • Simplecast
  • Contact
  • Jobs
  • Briefings
  • Terms of Use & Privacy
  • Disclosures
  • Conduct
  • Who We Are